Crizotinib efficacy in alk-positive advanced stage non-small cell lung cancer patients: A real-world experience from Turkey

Basit Öğe Kaydı
dc.contributor.authorKılıçkap, Sadettin
dc.contributor.authorÖztürk, Akın
dc.contributor.authorKaradurmuş, Nuri
dc.contributor.authorKorkmaz, Taner
dc.contributor.authorYumuk, Perran Fulden
dc.contributor.authorÇiçin, İrfan
dc.contributor.authorPaydaş, Semra
dc.contributor.authorÇılbır, Ebru
dc.contributor.authorSakalar, Teoman
dc.contributor.authorUysal, Mükremin
dc.contributor.authorÜskent, Necdet
dc.contributor.authorDemir, Nurcan
dc.contributor.authorSakin, Ayşegül
dc.contributor.authorTurhal, Nazım Serdar
dc.contributor.authorKeskin, Serhat
dc.contributor.authorTural, Deniz
dc.contributor.authorEralp, Yeşim
dc.contributor.authorBuğdaycı Başal, Fatma
dc.contributor.authorYaşar, Hatime Arzu
dc.contributor.authorSendur, Mehmet Ali Nahit
dc.contributor.authorDemirci, Umut
dc.contributor.authorÇubukçu, Erdem
dc.contributor.authorKaraağaç, Mustafa
dc.contributor.authorKaraca, Saziye
dc.contributor.authorTatlı, Ali Murat
dc.contributor.authorYetişyiğit, Tarkan
dc.contributor.authorUrvay, Semiha
dc.contributor.authorGürsoy, Pınar
dc.contributor.authorOyan Uluç, Başak
dc.contributor.authorTurna, Zeynep Hande
dc.contributor.authorKüçüköner, Mehmet
dc.contributor.authorÖlmez, Ömer Fatih
dc.contributor.authorÇabuk, Devrim
dc.contributor.authorŞeker, Mesut
dc.contributor.authorÜnal, Olçun Umut
dc.contributor.authorMeydan, Nezih
dc.contributor.authorOkutur, Sadi Kerem
dc.contributor.authorTunalı, Duygu
dc.date.accessioned10.07.201910:49:13
dc.date.accessioned2019-07-10T19:50:06Z
dc.date.available10.07.201910:49:13
dc.date.available2019-07-10T19:50:06Z
dc.date.issued2018
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı
dc.descriptionWOS: 000454014501235
dc.description.abstractBackground: Increasing evidence leads to a ratiocination that genetic heterogeneity of the lung adenocarcinoma patients with sensitive EGFR mutations may impact clinical responses and outcomes to EGFR-TKIs. Method: We performed targeted NGS with a gene panel covering 416 cancer-related genes to profile genetic characteristics of 69 lung adenocarcinoma patients with activating EGFR mutations and assessed the contribution of targeted NGS to exploration of genetic heterogeneity of such cohort. Result: We detected total 200 actionable genetic alterations (mean 2.9 variations per patient, range: 1-7 variations) in tumor DNA and 140 actionable genetic alterations (mean 2.0 variations per patient, range: 0-5 variations) in matched plasma ctDNA, respectively. The concurrent genes with the highest mutation rate were TP53 (observed in 72.5% patients), other uncommon EGFR mutations (observed in 21.7% patients), EGFR amplification (observed in 20.3% patients), RB1 (observed in 10.1% patients), PIK3CA (observed in 7.2% patients), and MYC (observed in 5.8% patients). NGS provides EGFR mutation detection in plasma with a test sensitivity of 88.2% and specificity of 100.0%.
dc.identifier.citationKılıçkap, S., Öztürk, A., Karadurmuş, N., Korkmaz, T., Yumuk, P., Çiçin, İ. ... Tunalı, D. (2018). Crizotinib efficacy in alk-positive advanced stage non-small cell lung cancer patients: A real-world experience from Turkey. Journal of Thoracic Oncology içinde (S477-S478. ss.).
dc.identifier.endpageS478
dc.identifier.issn1556-0864
dc.identifier.issn1556-1380
dc.identifier.issue10
dc.identifier.startpageS477
dc.identifier.urihttps://hdl.handle.net/20.500.12511/1881
dc.identifier.volume13
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.language.isoen
dc.publisherElsevier Science Inc
dc.relation.ispartofJournal of Thoracic Oncologyen_US
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectNSCLC
dc.subjectALK Inhibitor
dc.subjectCrizotinib
dc.titleCrizotinib efficacy in alk-positive advanced stage non-small cell lung cancer patients: A real-world experience from Turkey
dc.typeConference Object

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Ölmez, Ö..pdf
Boyut:
201.46 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Bildiri Koleksiyonu